These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 11288751)

  • 1. Mechanisms of action of glatiramer acetate in multiple sclerosis.
    Neuhaus O; Farina C; Wekerle H; Hohlfeld R
    Neurology; 2001 Mar; 56(6):702-8. PubMed ID: 11288751
    [No Abstract]   [Full Text] [Related]  

  • 2. Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetate.
    Windhagen A; Maniak S; Marckmann S; Lindert RB; Heidenreich F; Blasczyk R
    J Neurol Neurosurg Psychiatry; 2001 Mar; 70(3):415-6. PubMed ID: 11181881
    [No Abstract]   [Full Text] [Related]  

  • 3. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
    Wolinsky JS; Narayana PA; Johnson KP;
    Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with Glatiramer Acetate (Copaxone).
    Losy J; Michałowska-Wender G; Kurdyńska A; Wender M
    Folia Neuropathol; 2005; 43(3):153-5. PubMed ID: 16245210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS
    Neurology; 1998 Mar; 50(3):701-8. PubMed ID: 9521260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glatiramer acetate: evidence for a dual mechanism of action.
    Blanchette F; Neuhaus O
    J Neurol; 2008 Mar; 255 Suppl 1():26-36. PubMed ID: 18317674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended use of glatiramer acetate (Copaxone) for MS.
    Greenstein JI
    Neurology; 1999 Mar; 52(4):897-8. PubMed ID: 10078765
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate.
    Frese A; Bethke F; Lüdemann P; Stögbauer F
    J Neurol; 2000 Sep; 247(9):713. PubMed ID: 11081814
    [No Abstract]   [Full Text] [Related]  

  • 9. Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis.
    Ziemssen T
    Adv Exp Med Biol; 2004; 541():111-34. PubMed ID: 14977211
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.
    Dhib-Jalbut S
    Neurology; 2002 Apr; 58(8 Suppl 4):S3-9. PubMed ID: 11971121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glatiramer acetate in multiple sclerosis.
    Mezzapesa DM; Rovaris M; Filippi M
    Expert Rev Neurother; 2005 Jul; 5(4):451-8. PubMed ID: 16026228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-benefit assessment of glatiramer acetate in multiple sclerosis.
    Ziemssen T; Neuhaus O; Hohlfeld R
    Drug Saf; 2001; 24(13):979-90. PubMed ID: 11735654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis.
    Sormani MP; Bruzzi P; Comi G; Filippi M
    Mult Scler; 2005 Aug; 11(4):447-9. PubMed ID: 16042228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.
    Yong VW
    Neurology; 2002 Sep; 59(6):802-8. PubMed ID: 12349849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis: monotherapy rules.
    Hauser SL; Josephson SA; Johnston SC
    Ann Neurol; 2013 Mar; 73(3):A5-6. PubMed ID: 23596013
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.
    Weiner HL
    Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3333-5. PubMed ID: 10097037
    [No Abstract]   [Full Text] [Related]  

  • 17. Copolymer 1: a most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability.
    Wolinsky JS
    Neurology; 1995 Jul; 45(7):1245-7. PubMed ID: 7617175
    [No Abstract]   [Full Text] [Related]  

  • 18. The cost of delaying treatment in multiple sclerosis: what is lost is not regained.
    Zwibel H
    Neurology; 2002 Feb; 58(4):667; author reply 668. PubMed ID: 11865160
    [No Abstract]   [Full Text] [Related]  

  • 19. [Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis].
    Gusev EI; Boĭko AN; Pozer Ch
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(4):33-6. PubMed ID: 10319395
    [No Abstract]   [Full Text] [Related]  

  • 20. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".
    Richert ND
    Neurology; 2002 May; 58(9):1440-1; author reply 1441-2. PubMed ID: 12011306
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.